Form 8-K - Current report:
SEC Accession No. 0001171843-25-001689
Filing Date
2025-03-25
Accepted
2025-03-25 16:01:28
Documents
15
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_032525.htm   iXBRL 8-K 25371
2 EXHIBIT 99.1 exh_991.htm EX-99.1 60343
  Complete submission text file 0001171843-25-001689.txt   315787

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE crvs-20250325.xsd EX-101.SCH 3271
4 XBRL DEFINITION FILE crvs-20250325_def.xml EX-101.DEF 26197
5 XBRL LABEL FILE crvs-20250325_lab.xml EX-101.LAB 35951
6 XBRL PRESENTATION FILE crvs-20250325_pre.xml EX-101.PRE 24855
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_032525_htm.xml XML 5087
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 25768205
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)